Safety and efficacy of combining afatinib and whole-brain radiation therapy in treating brain metastases from EGFR-mutated NSCLC: a case report and literature review
暂无分享,去创建一个
V. Tombolini | E. Cortesi | A. Gelibter | D. Musio | N. Bulzonetti | F. De Felice | F. Marampon | M. Parisi | Pier Rodolfo Cicco | Maria Serpone
[1] M. Ahluwalia,et al. Current approaches to the management of brain metastases , 2020, Nature Reviews Clinical Oncology.
[2] A. Drilon,et al. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). , 2019, Lung cancer.
[3] Yanxin Chen,et al. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis , 2019, BMC Cancer.
[4] J. Hung,et al. Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases , 2019, Cancers.
[5] W. Liang,et al. EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases. , 2019, Translational lung cancer research.
[6] G. Fabbrocini,et al. Retrospective Analysis of Skin Toxicity in Patients under Anti-EGFR Tyrosine Kinase Inhibitors: Our Experience in Lung Cancer , 2019, Open access Macedonian journal of medical sciences.
[7] D. Lin,et al. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study , 2019, Cancer management and research.
[8] M. Deng,et al. Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients , 2018, Front. Oncol..
[9] Yiping Zhang,et al. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis , 2018, Archives of medical science : AMS.
[10] Lingxiang Liu,et al. Efficacy and Safety of Radiotherapy Plus EGFR-TKIs in NSCLC Patients with Brain Metastases: A Meta-Analysis of Published Data , 2018, Translational oncology.
[11] M. Hochmair. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease , 2018, Targeted Oncology.
[12] Xiao Lu,et al. Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis , 2017, Oncotarget.
[13] Allan Hackshaw,et al. Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis , 2017, International journal of cancer.
[14] C. Eze,et al. Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature , 2017, Front. Oncol..
[15] A. Wolfson,et al. Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy , 2016, Dermatology and Therapy.
[16] T. Jiang,et al. Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis , 2016, Cancer medicine.
[17] Yueh-Fu Fang,et al. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis , 2015, Medicine.
[18] Xufeng Chen,et al. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation , 2015, Oncotarget.
[19] A. Hackshaw,et al. Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases , 2014, Journal of the National Cancer Institute.
[20] Joe Y. Chang,et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Marco van Vulpen,et al. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). , 2002, Oncology reports.
[22] J. Vansteenkiste,et al. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.